Search: onr:"swepub:oai:DiVA.org:uu-343357" >
Smoking and pre-exi...
Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus.
-
- Parodis, Ioannis (author)
- Karolinska Institutet,Karolinska University Hospital
-
- Sjöwall, Christopher (author)
- Linköping University,Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten,Region Östergötland, Reumatologiska kliniken i Östergötland
-
- Jönsen, Andreas (author)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund SLE Research Group,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups
-
show more...
-
- Ramsköld, Daniel (author)
- Karolinska Institutet,Karolinska University Hospital
-
- Zickert, Agneta (author)
- Karolinska Institutet,Karolinska University Hospital
-
- Frodlund, Martina (author)
- Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten
-
- Sohrabian, Azita (author)
- Uppsala universitet,Klinisk immunologi,Uppsala University, Uppsala, Sweden
-
- Arnaud, Laurent (author)
- Karolinska University Hospital, Sweden; University of Strasbourg, France
-
- Rönnelid, Johan (author)
- Uppsala universitet,Klinisk immunologi,Uppsala University, Uppsala, Sweden
-
- Malmström, Vivianne (author)
- Karolinska Institutet,Karolinska University Hospital
-
- Bengtsson, Anders A. (author)
- Lund University,Lunds universitet,Reumatologi och molekylär skelettbiologi,Sektion III,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Lund SLE Research Group,Forskargrupper vid Lunds universitet,Rheumatology,Section III,Department of Clinical Sciences, Lund,Faculty of Medicine,Lund University Research Groups
-
- Gunnarsson, Iva (author)
- Karolinska Institutet,Karolinska University Hospital
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2017
- 2017
- English.
-
In: Autoimmunity Reviews. - : Elsevier BV. - 1568-9972 .- 1873-0183. ; 16:4, s. 343-351
- Related links:
-
http://dx.doi.org/10...
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
http://kipublication...
-
https://lup.lub.lu.s...
-
show less...
Abstract
Subject headings
Close
- OBJECTIVES: Belimumab is the first biologic drug approved for Systemic Lupus Erythematosus (SLE). Here, we aimed to investigate the effects of belimumab on clinical and serologic outcomes, and sought to identify predictors of treatment response in three Swedish real-life settings.METHODS: Fifty-eight patients were enrolled at initiation of belimumab and followed longitudinally for up to 53months. Surveillance outcomes included the SLE Disease Activity Index 2000 (SLEDAI-2K), 100mm Visual Analogue Scales for Physician's Global Assessment (PGA), fatigue, pain and general health, and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Assessment of treatment response included the SLE responder index (SRI). B lymphocyte stimulator (BLyS) levels were determined using ELISA.RESULTS: SLEDAI-2K (median baseline score: 8.0; IQR: 4.0-13.8), PGA and corticosteroid use decreased during therapy, and patients reported improvements on fatigue, pain, and general health (p<0.0001 for all). SDI scores remained stable (p=0.08). Patients with baseline SDI scores >1 showed decreased probability and prolonged time to attain SRI response (HR: 0.449; 95% CI: 0.208-0.967), as did current smokers compared with non-smokers (HR: 0.103; 95% CI: 0.025-0.427). In contrast, baseline BLyS levels ≥1.2ng/mL predicted increased probability and shorter time to attain SRI response (HR: 2.566; 95% CI: 1.222-5.387).CONCLUSIONS: Disease activity and corticosteroid usage decreased, patient-reported outcomes improved, and no significant organ damage was accrued during follow-up. Smoking and organ damage predicted reduced treatment efficacy. These findings might contribute to a better selection of patients who are likely to benefit from belimumab.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)
Keyword
- BAFF
- BLyS
- Belimumab
- Biologics
- Systemic lupus erythematosus
- BAFF
- Belimumab
- Biologics
- BLyS
- Systemic lupus erythematosus
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Parodis, Ioannis
-
Sjöwall, Christo ...
-
Jönsen, Andreas
-
Ramsköld, Daniel
-
Zickert, Agneta
-
Frodlund, Martin ...
-
show more...
-
Sohrabian, Azita
-
Arnaud, Laurent
-
Rönnelid, Johan
-
Malmström, Vivia ...
-
Bengtsson, Ander ...
-
Gunnarsson, Iva
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Rheumatology and ...
- Articles in the publication
-
Autoimmunity Rev ...
- By the university
-
Uppsala University
-
Linköping University
-
Karolinska Institutet
-
Lund University